<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789723</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-FUS-12-102</org_study_id>
    <nct_id>NCT01789723</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn</brief_title>
  <official_title>An Open Label, Multicenter, Dose Finding, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Receiving Folotyn® (Pralatrexate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or
      reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, uncontrolled, nonrandomized, multicenter, dose finding, Phase 1 study
      primarily to determine the optimal dose and schedule of Fusilev to prevent or reduce
      Folotyn-related Grade 3 or higher oral Mucositis.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose and schedule of Fusilev to prevent or reduce mucositis</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>The patient will be seen in the clinic for an oral mucositis assessment at baseline. During the 6 weeks of Folotyn treatment, oral mucositis assessment will be performed weekly prior to each Folotyn dose and again on Day 4 (prior to the Fusilev dose when applicable) by a qualified health care professional. Patients will complete an Oral Mucositis Daily Questionnaire (OMQD) starting at Day 1 of Week 1 and ending at the End of Treatment Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of Fusilev on Folotyn related Oral Mucositis</measure>
    <time_frame>7 weeks</time_frame>
    <description>To determine the impact of Fusilev on the number of Folotyn-related dose modifications secondary to oral mucositis To determine the impact of Fusilev on the frequency of Folotyn-related oral mucositis To determine the impact of Fusilev on the number of Folotyn doses delivered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between Fusilev use and oral mucositis</measure>
    <time_frame>7 weeks</time_frame>
    <description>To determine the relationship between Fusilev use and oral mucositis as a function of the pretreatment homocysteine (HCY) and methylmalonic acid (MMA) levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To determine overall response rate (ORR) of Folotyn in relapsed or refractory Non-Hodgkin's lymphoma other than PTCL</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Fusilev - 10 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.
Folotyn: 30 mg/m2 once weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Fusilev - 6 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.
Folotyn: 30 mg/m2 once weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Fusilev - 4 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.
Folotyn: 30 mg/m2 once weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Fusilev - 2 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.
Folotyn: 30 mg/m2 once weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Fusilev - 1 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fusilev: 5 mg/m2 once on Day 2.
Folotyn: 30 mg/m2 once weekly for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fusilev</intervention_name>
    <description>Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.</description>
    <arm_group_label>Cohort 1: Fusilev - 10 doses</arm_group_label>
    <arm_group_label>Cohort 2: Fusilev - 6 doses</arm_group_label>
    <arm_group_label>Cohort 3: Fusilev - 4 doses</arm_group_label>
    <arm_group_label>Cohort 4: Fusilev - 2 doses</arm_group_label>
    <arm_group_label>Cohort 5: Fusilev - 1 dose</arm_group_label>
    <other_name>Fusilev - (Levoleucovorin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folotyn</intervention_name>
    <description>A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.</description>
    <arm_group_label>Cohort 1: Fusilev - 10 doses</arm_group_label>
    <arm_group_label>Cohort 2: Fusilev - 6 doses</arm_group_label>
    <arm_group_label>Cohort 3: Fusilev - 4 doses</arm_group_label>
    <arm_group_label>Cohort 4: Fusilev - 2 doses</arm_group_label>
    <arm_group_label>Cohort 5: Fusilev - 1 dose</arm_group_label>
    <other_name>Folotyn - (Pralatrexate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Patients with relapsed or refractory NHL who are eligible for Folotyn treatment.
             Patient has histologically/cytologically confirmed, measurable (lesion or node ≥ 2 cm
             by computed tomography [CT]

          -  Progressive disease or persistent disease after at least 1 prior treatment

          -  ECOG performance status ≤ 2

          -  Adequate hematological, hepatic, and renal function

        Exclusion Criteria:

          -  Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of
             the cervix)

          -  Congestive heart failure

          -  Uncontrolled hypertension

          -  Known human immunodeficiency virus (HIV)-positive diagnosis

          -  Active uncontrolled infection, underlying medical condition, or other serious illness
             that would impair the ability of the patient to receive protocol treatment

          -  Major surgery within 14 days of enrollment

          -  Pregnant or breast-feeding women

          -  Symptomatic central nervous system (CNS) metastases or lesions for which treatment is
             required. Patients who received prophylactic CNS treatment are eligible

          -  Previous exposure to pralatrexate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Sawas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2013</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminopterin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

